Research programme: antimalarials - PLIVA/WRAIR

Drug Profile

Research programme: antimalarials - PLIVA/WRAIR

Alternative Names: Antimalarials research programme - PLIVA/WRAIR; Azithromycin analogues research programme - PLIVA/WRAIR; Research programme: antimalarials - Pliva Research Institute/WRAIR

Latest Information Update: 16 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PLIVA Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 05 May 2006 GlaxoSmithKline aquires the research arm of PLIVA
  • 20 Jul 2005 Preclinical trials in Malaria in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top